Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mortensen, J
Right arrow Articles by Groth, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mortensen, J
Right arrow Articles by Groth, S

Chest, Vol 103, 805-811, Copyright © 1993 by American College of Chest Physicians


ARTICLES

Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis

J Mortensen, A Hansen, M Falk, IK Nielsen and S Groth
Department of Clinical Physiology, Rigshospitalet, State University Hospital, Copenhagen, Denmark.

STUDY OBJECTIVE: It has been suggested that the defective cyclic AMP- dependent Cl- secretion and the increased Na+ absorption from airway epithelia in cystic fibrosis (CF) may lead to dehydrated secretions and impaired mucociliary clearance. Beta 2-adrenergic agonists are unable to stimulate the Cl- transport in the airways in CF while being able to do so in normal airways. Thus, we questioned whether the beta 2- adrenergic agonist, terbutaline, would improve mucociliary clearance in patients with CF as it does in healthy subjects. DESIGN: A double- blind, randomized cross-over trial. SETTING: Whole lung and regional mucociliary clearance of a radioaerosol was measured for 3 h by gamma camera. One minute of cough clearance was measured at 3 h. Pulmonary function was measured before and after the gamma camera study. PATIENTS: Ten young patients with CF were studied; three were heterozygous for deletion of the phenylalanine at position 508 (delta F508), and seven were delta F508 homozygous. Interventions: Inhalation of 1 mg of terbutaline (4 puffs) and placebo via a metered-dose inhaler by spacer. MEASUREMENTS AND RESULTS: The largest differences in tracheobronchial retention (percent) in the whole lung and regional lung zones were generally observed within 1 h after terbutaline and placebo treatment: whole lung (mean +/- SD), 60 +/- 22 percent and 63 +/- 20 percent; central zone, 41 +/- 19 percent and 50 +/- 25 percent; midzones, 65 +/- 27 percent and 63 +/- 19 percent; and peripheral zones, 77 +/- 28 percent and 72 +/- 28 percent, respectively [p > 0.1]. Whereas none of these differences was statistically significant, subanalyses suggested an improvement in mucociliary clearance by terbutaline in the three delta F508 heterozygous patients but not in the seven delta F508 homozygous patients. One minute of voluntary coughing resulted in clearance of less than 8 percent of the initial radioactivity, with a trend of more peripheral zone clearance after terbutaline compared with placebo. A small significant decrease in airway resistance was detected 3 h after terbutaline. CONCLUSIONS: We conclude that 1 mg of terbutaline did not improve mucociliary clearance significantly in the patients with CF. Also, the effect of terbutaline was much less than demonstrated earlier in healthy subjects. This is consistent with earlier findings of a lack of beta-adrenergic modulation of Cl- transport in CF. Thus, no rehydration of the dry mucus in CF is expected, and a possible beta 2-agonist-induced increase in ciliary beating would have only a minor effect on overall mucociliary clearance.


This article has been cited by other articles:


Home page
CLIN PEDIATRHome page
D. Seth, S. Chawla, R. Shy, and D. Kamat
Dysphonia
Clinical Pediatrics, April 1, 2007; 46(3): 283 - 289.
[PDF]


Home page
NEJMHome page
S. H. Donaldson, W. D. Bennett, K. L. Zeman, M. R. Knowles, R. Tarran, and R. C. Boucher
Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline
N. Engl. J. Med., January 19, 2006; 354(3): 241 - 250.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
I M Balfour-Lynn and J S Elborn
"CF asthma": what is it and what do we do about it?
Thorax, August 1, 2002; 57(8): 742 - 748.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. W. Ramsey
Management of Pulmonary Disease in Patients with Cystic Fibrosis
N. Engl. J. Med., July 18, 1996; 335(3): 179 - 188.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American College of Chest Physicians.